At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 15,828 enrolled
Drug / intervention
Darapladib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
In Brief
A Phase 3 clinical trial evaluating Darapladib and Placebo for Atherosclerosis. Completed, enrolled 15,828 participants across 650 sites in 39 countries.
Detailed Summary
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerosis
CountriesArgentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark, Estonia, France, Germany, Greece, Hong Kong, Hungary, India, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Pakistan, Peru, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartDec 2008
Primary CompletionOct 2013
Study CompletionOct 2013
TodayJul 2026
First PostedDec 1, 2008
Enrollment StartDec 1, 2008
Primary CompletionOct 1, 2013
Study CompletionOct 17, 2013
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 17.6 years ago
Interventions
Darapladibdrug
Lp-PLA2 inhibitor administered in addition to standard therapy
Placebodrug
Placebo administered in addition to standard therapy